Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention

Nutrition

Volumn 32, Issue 2, 2016, Pages 157-165

  Yamagishi, Sho ichi ^a   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Aging; Cardiometabolic disorder; Diet; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

AGING; ARTERIAL STIFFNESS; CARDIAC STIFFNESS; CELL REGENERATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIET; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART DISEASE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; WOUND HEALING; ALZHEIMER DISEASE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DISEASE COURSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOLOGY;

AGING; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84955656573     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2015.08.001     Document Type: Review

References (134)

1. Monnier V.M. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 1990, 45:B105-B111.
2. Stevens V.J., Rouzer C.A., Monnier V.M., Cerami A. Diabetic cataract formation: Potential role of glycosylation of lens crystallins. Proc Natl Acad Sci U S A 1978, 75:2918-2922.
3. Schmidt A.M., Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2000, 2:430-436.
4. Yamagishi S., Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005, 11:2279-2299.
5. Kilhovd B.K., Juutilainen A., Lehto S., Rönnemaa T., Torjesen P.A., Hanssen K.F., et al. Increased serum levels of advanced glycation end products predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study. Diabetologia 2007, 50:1409-1417.
6. Yamagishi S., Matsui T. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr Drug Targets 2010, 11:875-881.
7. Nin J.W., Jorsal A., Ferreira I., Schalkwijk C.G., Prins M.H., Parving H.H., et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes Care 2011, 34:442-447.
8. Yamagishi S. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders. Rejuvenation Res 2012, 15:564-572.
9. Vlassara H., Striker G.E. Advanced glycation end products in diabetes and diabetic complications. Endocrinol Metab Clin North Am 2013, 42:697-719.
10. Ward M.S., Fortheringham A.K., Cooper M.E., Forbes J.M. Targeting advanced glycation end products and mitochondrial dysfunction in cardiovascular disease. Curr Opin Pharmacol 2013, 13:654-661.
11. Fukami K., Yamagishi S., Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des 2014, 20:2395-2402.
12. Kajikawa M., Nakashima A., Fujimura N., Maruhashi T., Iwamoto Y., Iwamoto A., et al. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 2015, 38:119-125.
13. Yamagishi S.I., Fukami K., Matsui T. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. Int J Cardiol 2015, 185:263-268.
14. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J., Dahms W., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: Relevance of glycated collagen products versus HbA1 c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999, 48:870-880.
15. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111. DCCT Skin Collagen Ancillary Study Group.
16. Sun J.K., Keenan H.A., Cavallerano J.D., Asztalos B.F., Schaefer E.J., Sell D.R., et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: The joslin 50-year medalist study. Diabetes Care 2011, 34:968-974.
17. Fukami K., Taguchi K., Yamagishi S., Okuda S. Receptor for advanced glycation endproducts and progressive kidney disease. Curr Opin Nephrol Hypertens 2015, 24:54-60.
18. Unoki H., Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008, 14:987-989.
19. Yamagishi S., Nakamura K., Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009, 60:174-178.
20. Tahara N., Yamagishi S., Matsui T., Takeuchi M., Nitta Y., Kodama N., et al. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012, 30:42-48.
21. Takeuchi M., Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008, 14:973-978.
22. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011, 12:2096-2102.
23. Ojima A., Matsui T., Maeda S., Takeuchi M., Inoue H., Higashimoto Y., et al. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab Invest 2014, 94:422-429.
24. Yamagishi S.I., Matsui T., Fukami K. Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res 2015, 18:48-56.
25. Vlassara H. Advanced glycation in health and disease: Role of the modern environment. Ann N Y Acad Sci 2005, 1043:452-460.
26. Yamagishi S., Ueda S., Okuda S. Food-derived advanced glycation end products (AGEs): A novel therapeutic target for various disorders. Curr Pharm Des 2007, 13:2832-2836.
27. Vlassara H., Striker G.E. AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol 2011, 7:526-539.
28. Luevano-Contreras C., Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients 2010, 2:1247-1265.
29. Han L., Li L., Li B., Zhao D., Li Y., Xu Z., et al. Review of the characteristics of food-derived and endogenous ne-carboxymethyllysine. J Food Prot 2013, 76:912-918.
30. Poulsen M.W., Hedegaard R.V., Andersen J.M., de Courten B., Bügel S., Nielsen J., et al. Advanced glycation end products in food and their effects on health. Food Chem Toxicol 2013, 60:10-37.
31. Kellow N.J., Savige G.S. Dietary advanced glycation end product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: A systematic review. Eur J Clin Nutr 2013, 67:239-248.
32. Uribarri J., Cai W., Sandu O., Peppa M., Goldberg T., Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005, 1043:461-466.
33. Jägerstad M., Skog K. Genotoxicity of heat-processed foods. Mutat Res 2005, 574:156-172.
34. Lindenmeier M., Faist V., Hofmann T. Structural and functional characterization of pronyl-lysine, a novel protein modification in bread crust melanoidins showing in vitro antioxidative and phase I/II enzyme modulating activity. J Agric Food Chem 2002, 50:6997-7006.
35. Eskin N.A.M., Ho C.T., Shahidi F. Browning reactions in foods. Biochemistry of Foods 2013, 245-289. Academic Press, San Diego. N.A. Michael Eskin, F. Shahidi (Eds.).
36. Uribarri J., Woodruff S., Goodman S., Cai W., Chen X., Pyzik R., et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010, 110:911-916.
37. Goldberg T., Cai W., Peppa M., Dardaine V., Baliga B.S., Uribarri J., et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004, 104:1287-1291.
38. Takeuchi M., Takino J., Furuno S., Shirai H., Kawakami M., Muramatsu M., et al. Assessment of the concentrations of various advanced glycation end products in beverages and foods that are commonly consumed in Japan. PLoS One 2015, 10:e0118652.
39. Koschinsky T., He C.J., Mitsuhashi T., Bucala R., Liu C., Buenting C., et al. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997, 94:6474-6479.
40. He C., Sabol J., Mitsuhashi T., Vlassara H. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999, 48:1308-1315.
41. Degen J., Vogel M., Richter D., Hellwig M., Henle T. Metabolic transit of dietary methylglyoxal. J Agric Food Chem 2013, 61:10253-10260.
42. Degen J., Beyer H., Heymann B., Hellwig M., Henle T. Dietary influence on urinary excretion of 3-deoxyglucosone and its metabolite 3-deoxyfructose. J Agric Food Chem 2014, 62:2449-2456.
43. Hellwig M., Geissler S., Matthes R., Peto A., Silow C., Brandsch M., et al. Transport of free and peptide-bound glycated amino acids: Synthesis, transepithelial flux at Caco-2 cell monolayers, and interaction with apical membrane transport proteins. Chembiochem 2011, 12:1270-1279.
44. Geissler S., Hellwig M., Zwarg M., Markwardt F., Henle T., Brandsch M. Transport of the advanced glycation end products alanylpyrraline and pyrralylalanine by the human proton-coupled peptide transporter hPEPT1. J Agric Food Chem 2010, 58:2543-2547.
45. Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients with Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC. Diabetes 2015, 64:631-642. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.
46. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014, 2:793-800. DCCT/EDIC research group.
47. Nathan D.M., Lachin J., Cleary P., Orchard T., Brillon D.J., Backlund J.Y., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348:2294-2303. Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group.
48. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
49. Orchard T.J., Nathan D.M., Zinman B., Cleary P., Brillon D., Lachin J.M. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015, 313:45-53. Writing Group for the DCCT/EDIC Research Group.
50. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
51. LaCroix A.Z., Lang J., Scherr P., Wallace R.B., Cornoni-Huntley J., Berkman L., et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991, 324:1619-1625.
52. Teo K.K., Ounpuu S., Hawken S., Pandey M.R., Valentin V., Hunt D., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet 2006, 368:647-658. INTERHEART Study Investigators.
53. Yamagishi S., Matsui T., Nakamura K. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers. Med Hypotheses 2008, 71:259-261.
54. Cerami C., Founds H., Nicholl I., Mitsuhashi T., Giordano D., Vanpatten S., et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 1997, 94:13915-13920.
55. Fukushima Y., Daida H., Morimoto T., Kasai T., Miyauchi K., Yamagishi S., et al. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: The JAPAN-ACS sub-study. Cardiovasc Diabetol 2013, 12:5. JAPAN-ACS Investigators.
56. Li G., Zhang P., Wang J., Gregg E.W., Yang W., Gong Q., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet 2008, 371:1783-1789.
57. Yamagishi S., Matsui T., Nakamura K. Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes. Med Hypotheses 2008, 71:876-878.
58. Lin R.Y., Reis E.D., Dore A.T., Lu M., Ghodsi N., Fallon J.T., et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002, 163:303-311.
59. Lin R.Y., Choudhury R.P., Cai W., Lu M., Fallon J.T., Fisher E.A., et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003, 168:213-220.
60. Grossin N., Auger F., Niquet-Leridon C., Durieux N., Montaigne D., Schmidt A.M., et al. Dietary CML-enriched protein induces functional arterial aging in a RAGE-dependent manner in mice. Mol Nutr Food Res 2015, 59:927-938.
61. Chen S.X., Song T., Zhou S.H., Liu Y.H., Wu S.J., Liu L.Y. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats. Eur J Pharmacol 2008, 584:368-375.
62. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., Dardaine V., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002, 99:15596-15601.
63. Cai W., He J.C., Zhu L., Peppa M., Lu C., Uribarri J., et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox- sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004, 110:285-291.
64. Zill H., Bek S., Hofmann T., Huber J., Frank O., Lindenmeier M., et al. RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 2003, 300:311-315.
65. Negrean M., Stirban A., Stratmann B., Gawlowski T., Horstmann T., Götting C., et al. Effects of low- and high-advanced glycation end product meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007, 85:1236-1243.
66. Uribarri J., Stirban A., Sander D., Cai W., Negrean M., Buenting C.E., et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007, 30:2579-2582.
67. Stirban A., Negrean M., Götting C., Uribarri J., Gawlowski T., Stratmann B., et al. Dietary advanced glycation endproducts and oxidative stress: In vivo effects on endothelial function and adipokines. Ann N Y Acad Sci 2008, 1126:276-279.
68. Tahara N., Yamagishi S., Takeuchi M., Honda A., Tahara A., Nitta Y., et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care 2012, 35:2618-2625.
69. Golia E., Limongelli G., Natale F., Fimiani F., Maddaloni V., Pariggiano I., et al. Inflammation and cardiovascular disease: From pathogenesis to therapeutic target. Curr Atheroscler Rep 2014, 16:435.
70. Fukami K., Yamagishi S., Iida S., Matsuoka H., Okuda S. Involvement of iron-evoked oxidative stress in smoking-related endothelial dysfunction in healthy young men. PLoS One 2014, 9:e89433.
71. Ando R., Ueda S., Yamagishi S., Miyazaki H., Kaida Y., Kaifu K., et al. Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diab Vasc Dis Res 2013, 10:436-441.
72. Ueda S., Yamagishi S., Yokoro M., Okuda S. Role of asymmetric dimethylarginine in cardiorenal syndrome. Curr Pharm Des 2014, 20:2448-2455.
73. Semba R.D., Gebauer S.K., Baer D.J., Sun K., Turner R., Silber H.A., et al. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr 2014, 144:1037-1042.
74. Semba R.D., Ang A., Talegawkar S., Crasto C., Dalal M., Jardack P., et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: The Energetics Study. Eur J Clin Nutr 2012, 66:3-9.
75. Poulsen M.W., Bak M.J., Andersen J.M., Monošík R., Giraudi-Futin A.C., Holst J.J., et al. Effect of dietary advanced glycation end products on postprandial appetite, inflammation, and endothelial activation in healthy overweight individuals. Eur J Nutr 2014, 53:661-672.
76. Roncero-Ramos I., Delgado-Andrade C., Tessier F.J., Niquet-Léridon C., Strauch C., Monnier V.M., et al. Metabolic transit of N(ε)-carboxymethyl-lysine after consumption of AGEs from bread crust. Food Funct 2013, 4:1032-1039.
77. Roncero-Ramos I., Niquet-Léridon C., Strauch C., Monnier V.M., Tessier F.J., Navarro M.P., et al. An advanced glycation end product (AGE)-rich diet promotes Nε-carboxymethyl-lysine accumulation in the cardiac tissue and tendons of rats. J Agric Food Chem 2014, 62:6001-6006.
78. Chen X., Mori T., Guo Q., Hu C., Ohsaki Y., Yoneki Y., et al. Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. Hypertens Res 2013, 36:361-367.
79. Crisóstomo J., Matafome P., Santos-Silva D., Rodrigues L., Sena C.M., Pereira P., et al. Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia disease in Wistar normal rats. Nutr Metab Cardiovasc Dis 2013, 23:1223-1230.
80. Semba R.D., Najjar S.S., Sun K., Lakatta E.G., Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 2009, 22:74-79.
81. Zhu Y., Lan F., Wei J., Chong B., Chen P., Huynh L., et al. Influence of dietary advanced glycation end products on wound healing in nondiabetic mice. J Food Sci 2011, 76:T5-T10.
82. Chen Q., Dong L., Wang L., Kang L., Xu B. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem Biophys Res Commun 2009, 381:192-197.
83. Ueda S., Yamagishi S., Matsui T., Noda Y., Ueda S., Jinnouchi Y., et al. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther 2012, 30:249-254.
84. Uribarri J., He J.C. The low AGE diet: A neglected aspect of clinical nephrology practice. Nephron 2015, 130:48-53.
85. Zheng F., He C., Cai W., Hattori M., Steffes M., Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002, 18:224-237.
86. Thallas-Bonke V., Coughlan M.T., Tan A.L., Harcourt B.E., Morgan P.E., Davies M.J., et al. Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. Nephrology (Carlton) 2013, 18:47-56.
87. Vlassara H., Uribarri J., Cai W., Goodman S., Pyzik R., Post J., et al. Effects of sevelamer on HbA1 c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 2012, 7:934-942.
88. Yubero-Serrano E.M., Woodward M., Poretsky L., Vlassara H., Striker G.E. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol 2015, 10:759-766. AGE-less Study Group.
89. Li M., Zeng M., He Z., Zheng Z., Qin F., Tao G., et al. Increased accumulation of protein-bound N(ε)-(carboxymethyl)lysine in tissues of healthy rats after chronic oral N(ε)-(carboxymethyl)lysine. J Agric Food Chem 2015, 63:1658-1663.
90. Elmhiri G., Mahmood D.F., Niquet-Leridon C., Jacolot P., Firmin S., Guigand L., et al. Formula-derived advanced glycation end products are involved in the development of long-term inflammation and oxidative stress in kidney of IUGR piglets. Mol Nutr Food Res 2015, 59:939-947.
91. Sebekova K., Faist V., Hofmann T., Schinzel R., Heidland A. Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am J Kidney Dis 2003, 41:S48-S51.
92. Harcourt B.E., Sourris K.C., Coughlan M.T., Walker K.Z., Dougherty S.L., Andrikopoulos S., et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 2011, 80:190-198.
93. Vlassara H., Cai W., Goodman S., Pyzik R., Yong A., Chen X., et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009, 94:4483-4491.
94. Uribarri J., Peppa M., Cai W., Goldberg T., Lu M., Baliga S., et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003, 42:532-538.
95. Uribarri J., Peppa M., Cai W., Goldberg T., Lu M., He C., et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003, 14:728-731.
96. Peppa M., Uribarri J., Cai W., Lu M., Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004, 43:690-695.
97. Nongnuch A., Davenport A. The effect of vegetarian diet on skin autofluorescence measurements in haemodialysis patients. Br J Nutr 2015, 113:1040-1043.
98. Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997, 62:S23-S38.
99. Ueda S., Yamagishi S., Takeuchi M., Kohno K., Shibata R., Matsumoto Y., et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006, 12:180-184.
100. Tahara N., Yamagishi S., Kodama N., Tahara A., Honda A., Nitta Y., et al. Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT. J Clin Endocrinol Metab 2015, 100:E739-E747.
101. Hyogo H., Chayama K., Yamagishi S. Nonalcoholic fatty liver disease and cardiovascular disease. Curr Pharm Des 2014, 20:2403-2411.
102. Yamagishi S., Adachi H., Takeuchi M., Enomoto M., Furuki K., Matsui T., et al. Serum level of advanced glycation end products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res 2007, 39:845-848.
103. Tahara N., Imaizumi T., Takeuchi M., Yamagishi S.I. Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men. Oxid Med Cell Longev 2010, 3:262-265.
104. Tahara N., Yamagishi S., Tahara A., Ishibashi M., Hayabuchi N., Takeuchi M., et al. Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation. Int J Cardiol 2012, 158:461-462.
105. Hyogo H., Yamagishi S., Iwamoto K., Arihiro K., Takeuchi M., Sato T., et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:1112-1119.
106. Kimura Y., Hyogo H., Yamagishi S., Takeuchi M., Ishitobi T., Nabeshima Y., et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: Clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010, 45:750-757.
107. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006, 49:3094-3099.
108. Yoshida T., Yamagishi S., Matsui T., Nakamura K., Ueno T., Takeuchi M., et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2008, 36:237-243.
109. Unoki H., Bujo H., Yamagishi S., Takeuchi M., Imaizumi T., Saito Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007, 76:236-244.
110. Unoki-Kubota H., Yamagishi S., Takeuchi M., Bujo H., Saito Y. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett 2010, 17:1177-1181.
111. Hofmann S.M., Dong H.J., Li Z., Cai W., Altomonte J., Thung S.N., et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002, 51:2082-2089.
112. Sandu O., Song K., Cai W., Zheng F., Uribarri J., Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005, 54:2314-2319.
113. Ojima A., Matsui T., Nakamura N., Higashimoto Y., Ueda S., Fukami K., et al. DNA aptamer raised against advanced glycation end products (AGEs) improves glycemic control and decreases adipocyte size in fructose-fed rats by suppressing AGE-RAGE axis. Horm Metab Res 2015, 47:253-258.
114. Gurecká R., Koborová I., Janšáková K., Tábi T., Szöko É, Somoza V., et al. Prenatal dietary load of Maillard reaction products combined with postnatal Coca-Cola drinking affects metabolic status of female Wistar rats. Croat Med J 2015, 56:94-103.
115. Cai W., Uribarri J., Zhu L., Chen X., Swamy S., Zhao Z., et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol 2014, 60:832-838.
116. Chatzigeorgiou A., Kandaraki E., Piperi C., Livadas S., Papavassiliou A.G., Koutsilieris M., et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol 2013, 218:331-337.
117. Peppa M., He C., Hattori M., McEvoy R., Zheng F., Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003, 52:1441-1448.
118. Uribarri J., Cai W., Ramdas M., Goodman S., Pyzik R., Chen X., et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 2011, 34:1610-1616.
119. Mark A.B., Poulsen M.W., Andersen S., Andersen J.M., Bak M.J., Ritz C., et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 2014, 37:88-95.
120. Uribarri J., Cai W., Woodward M., Tripp E., Goldberg L., Pyzik R., et al. Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: A link between healthy and unhealthy obesity?. J Clin Endocrinol Metab 2015, 100:1957-1966.
121. Tantalaki E., Piperi C., Livadas S., Kollias A., Adamopoulos C., Koulouri A., et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens) 2014, 13:65-73.
122. Mericq V., Piccardo C., Cai W., Chen X., Zhu L., Striker G.E., et al. Maternally transmitted and food-derived glycotoxins: A factor preconditioning the young to diabetes?. Diabetes Care 2010, 33:2232-2237.
123. Luévano-Contreras C., Garay-Sevilla M.E., Wrobel K., Malacara J.M., Wrobel K. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 2013, 52:22-26.
124. Cai W., He J.C., Zhu L., Chen X., Wallenstein S., Striker G.E., et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: Association with increased AGER1 expression. Am J Pathol 2007, 170:1893-1902.
125. Cai W., He J.C., Zhu L., Chen X., Zheng F., Striker G.E., et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 2008, 173:327-336.
126. Semba R.D., Fink J.C., Sun K., Windham B.G., Ferrucci L. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: The Baltimore longitudinal study of aging. J Ren Nutr 2010, 20:74-81.
127. Semba R.D., Ferrucci L., Sun K., Patel K.V., Guralnik J.M., Fried L.P. Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women. Age Ageing 2009, 38:283-289.
128. Roy C.N., Semba R.D., Sun K., Bandinelli S., Varadhan R., Patel K.V., et al. Circulating selenium and carboxymethyl-lysine, an advanced glycation endproduct, are independent predictors of anemia in older community-dwelling adults. Nutrition 2012, 28:762-766.
129. Dalal M., Ferrucci L., Sun K., Beck J., Fried L.P., Semba R.D. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. J Gerontol A Biol Sci Med Sci 2009, 64:132-137.
130. Sun K., Semba R.D., Fried L.P., Schaumberg D.A., Ferrucci L., Varadhan R. Elevated serum carboxymethyl-Lysine, an advanced glycation end product, predicts severe walking disability in older women: The Women's Health and Aging Study I. J Aging Res 2012, 2012:586385.
131. Semba R.D., Fink J.C., Sun K., Bandinelli S., Guralnik J.M., Ferrucci L. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr 2009, 48:38-44.
132. Semba R.D., Bandinelli S., Sun K., Guralnik J.M., Ferrucci L. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: The InCHIANTI study. Eur J Appl Physiol 2010, 108:191-195.
133. Semba R.D., Ferrucci L., Sun K., Beck J., Dalal M., Varadhan R., et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res 2009, 21:182-190.
134. Semba R.D., Bandinelli S., Sun K., Guralnik J.M., Ferrucci L. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc 2009, 57:1874-1880.